xFUSION

Many individuals with diabetes struggle to adhere to their treatment regimens consistently, posing a significant health challenge. This issue affects a diverse range of patients globally, who face increased risks due to irregular management of their condition. By addressing this problem, FOH Future Of Health seeks to enhance patient outcomes and reduce the burden on healthcare systems. The collective expertise of health leaders at FOH aims to develop innovative solutions to improve adherence, ultimately contributing to the sustainability and efficiency of healthcare delivery worldwide.

Autonomous robotic solutions for pharmacy operations have the potential to transform how medications are stored, dispensed, verified, and delivered across hospital, retail, and community care settings. This challenge seeks innovative approaches that improve accuracy, speed, safety, and efficiency in pharmacy workflows while reducing manual burden on pharmacists and technicians. The target audience includes technology developers, robotics companies, healthcare innovators, pharmacy operators, and systems integrators who can address real-world operational constraints such as limited space, high prescription volumes, inventory complexity, regulatory compliance, and the need for seamless integration with existing pharmacy management systems. As healthcare systems face growing demand, workforce shortages, and increasing pressure to reduce medication errors, scalable autonomous solutions can help improve patient experience, optimize staff capacity, and strengthen resilience across the medication supply chain. We are looking for practical, implementable ideas that can support better outcomes, lower operational friction, and shape the future of pharmacy care.

Healthcare workforce burnout has become a critical global challenge, especially during periods of extreme pressure such as war, armed conflict, pandemics, and other prolonged emergencies. Physicians, nurses, paramedics, mental health professionals, and support staff are often required to work longer hours, make high-stakes decisions under uncertainty, and provide continuous care while facing emotional trauma, staff shortages, and limited resources. Over time, this intense environment leads to exhaustion, reduced wellbeing, lower retention, and risks to quality and safety of care. This challenge seeks solutions that can help prevent, identify, and reduce burnout among healthcare teams operating in crisis and high-intensity settings. The target audience includes hospitals, health systems, emergency responders, public health organizations, and frontline care teams. We are particularly interested in scalable, practical approaches that support resilience, mental health, workflow efficiency, and organizational readiness. Addressing this issue is essential not only for protecting healthcare workers, but also for maintaining system performance and ensuring patients continue to receive safe, effective, and compassionate care when it is needed most.

CBM - Complete Blood Morphology is advanced automation solution designed for hematology laboratories to fully digitize and autonomously perform the peripheral blood smear review process. Today, smear review remains a labor-intensive, manual, and highly specialized workflow that depends on trained professionals to examine blood cell morphology, identify abnormalities, and support clinical decision-making. This creates challenges related to staffing shortages, variability between reviewers, turnaround times, and scalability in high-volume lab environments. Our solution addresses this critical bottleneck by enabling a fully autonomous review process with no human intervention required in routine analysis. CBM is built for clinical laboratories, hospital hematology departments, and diagnostic centers seeking to improve efficiency, standardization, and operational capacity while maintaining high-quality diagnostic performance. By automating this essential step, the platform has the potential to reduce workload, minimize subjectivity, accelerate reporting, and support more consistent patient care. This is especially important as laboratories face rising demand, increasing complexity, and ongoing pressure to do more with fewer skilled resources.

Permitting Issuing For Construction addresses one of the most persistent bottlenecks in construction delivery: the slow, fragmented, and error-prone process of preparing, reviewing, approving, and issuing permit packages for construction. Project teams often manage drawings, revisions, compliance requirements, agency comments, and internal approvals across disconnected tools, creating delays, rework, missed deadlines, and increased project risk. This solution is intended for developers, architects, engineers, general contractors, permit coordinators, and municipal or regulatory stakeholders who need a more reliable and transparent path from design completion to construction authorization. The challenge is especially important in complex projects where multiple disciplines, jurisdictions, and approval gates must be aligned before work can begin. A strong solution should improve document control, workflow visibility, accountability, and turnaround time while reducing administrative burden and compliance gaps. By streamlining permitting and IFC issuance, organizations can accelerate project starts, improve collaboration, and lower the operational and financial impact of approval delays.

We have developed a next-generation immunotherapeutic platform designed to enhance the natural cytotoxic activity of Natural Killer (NK) cells against cancer and virally infected cells by suppressing key intracellular inhibitory checkpoints. Despite the strong promise of NK cell-based therapies, many current approaches are limited by complex cell isolation and expansion procedures, variable potency, and reduced functional persistence. Our strategy directly modulates the internal regulatory mechanisms that restrain NK cell killing, enabling stronger anti-tumor and antiviral responses both ex vivo and in vivo while addressing several practical and biological limitations of existing NK cell immunotherapies. This solution is highly relevant to biotechnology and pharmaceutical companies, immuno-oncology developers, cell therapy groups, and partners seeking broadly applicable immune-based platforms. Because NK cells play a central role in surveillance against malignant and infected cells, this technology has potential utility across a wide range of solid tumors, hematological cancers, and viral infections. By improving NK cell efficacy through a targeted intracellular mechanism, our approach offers a promising path toward more potent, scalable, and clinically meaningful immunotherapies.